Lansoprazole Tablet, Orally Disintegrating, Delayed Release
Product Images NDC 0093-3008

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 0093-3008). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 1)

Chemical structure of lansoprazole, showing its molecular arrangement including a benzimidazole ring, sulfinyl group, and a trifluoromethyl-substituted pyridine moiety.*

FDA Label Image

Figure-01 (Image 2)

A line graph depicting the mean severity of day heartburn over a 60-day treatment period for patients. The graph compares three groups: placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily. Severity is rated from 0 (none) to 3 (severe), showing a decline in heartburn severity with lansoprazole compared to placebo over time.*

FDA Label Image

Figure-02 (Image 3)

A line graph depicting the mean severity of night heartburn over days from the start of treatment for evaluable patients. The y-axis shows severity levels from 0 (none) to 3 (severe). Three lines compare placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily, illustrating decreased severity with treatment over approximately 60 days.*

FDA Label Image

Carton 15 mg (Image 4)

Packaging label for Lansoprazole 15 mg delayed-release orally disintegrating tablets by Teva Pharmaceuticals USA, Inc. The box contains 100 tablets (10 blister cards of 10 tablets each) and includes dosing and storage instructions. The label states it is prescription-only and highlights the presence of phenylalanine in each tablet.*

FDA Label Image

Carton 30 mg (Image 5)

Lansoprazole 30 mg Delayed-Release Orally Disintegrating Tablets packaging label from Teva Pharmaceuticals USA, Inc. The carton indicates 100 tablets in 10 blister cards of 10 tablets each. The label includes storage instructions, a barcode, and warnings for phenylketonurics and child safety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.